Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna (Nasdaq: SEPN) announced that CEO and co‑founder Jeffrey Finer, M.D., Ph.D. will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced that CEO and co‑founder Jeffrey Finer, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast of the presentation will be available in the company's investor relations section at www.septerna.com, and the webcast will be archived for at least 30 days after the presentation.
Details
News Market Reaction – SEPN
On Dec 17, the day this news came out, SEPN closed 1.22% above the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 13, 2026
- Scheduled conference presentation
- Presentation time
- 3:45 p.m. PT
- J.P. Morgan Healthcare Conference slot
- Webcast archive period
- 30 days
- Minimum time presentation replay available
Historical Context
-
Announced participation in Evercore healthcare conference with webcast and 30-day archive.
-
Reported profitable Q3 2025 and pipeline progress including SEP-479 and SEP-631.
-
Planned participation in November investor events with live webcasts and archives.
-
Added experienced biotech leader to Board and chair of new R&D Committee.
-
Announced September conference presentations with webcasts and 30-day replay access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
g protein-coupled receptor (gpcr) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco.
A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.